A Phase Ib, Double-blind, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Different Dosage Levels of Ebola Chimpanzee Adenovirus Vector Vaccine VRC-EBOAdc069-00-vp (cAd3-EBO) in Healthy Adults, 18-65 Years of Age, in Bamako, Mali

Trial Profile

A Phase Ib, Double-blind, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Different Dosage Levels of Ebola Chimpanzee Adenovirus Vector Vaccine VRC-EBOAdc069-00-vp (cAd3-EBO) in Healthy Adults, 18-65 Years of Age, in Bamako, Mali

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs VRC-EBOADC069-00-VP (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
    • 06 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 06 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top